Literature DB >> 11943732

Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity.

Luis Hernández1, Sílvia Beà, Beatriz Bellosillo, Magda Pinyol, Brunangelo Falini, Antonino Carbone, German Ott, Andreas Rosenwald, Alberto Fernández, Karen Pulford, David Mason, Stephan W Morris, Eugenio Santos, Elias Campo.   

Abstract

Anaplastic large cell lymphomas are associated with chromosomal aberrations involving the anaplastic lymphoma kinase (ALK) gene at 2p23 that result in the expression of novel chimeric ALK proteins with transforming properties. In most of these tumors, the t(2;5)(p23;q35) generates the NPM-ALK fusion gene. However, several studies have now demonstrated that genes other than NPM may be fused to the ALK gene. We have recently described two different ALK rearrangements involving the TRK-fused gene (TFG) in which the same portion of ALK was fused to different length fragments of the 5' TFG region. These two rearrangements encoded chimeric proteins of 85 kd (TFG-ALK(S)) and 97 kd (TFG-ALK(L)), respectively. In this study, we have identified a new ALK rearrangement in which the catalytic domain of ALK was fused to a larger fragment of the TFG gene (TFG-ALK(XL)), encoding for a fusion protein of 113 kd. Genomic analysis of these three TFG-ALK rearrangements revealed that the TFG breakpoints occur at introns 3, 4, and 5, respectively, whereas the ALK breakpoints always occur in the same intron. No homologous regions or known recombination sequences were found in these regions. Transfection experiments using NIH-3T3 fibroblasts showed a similar transforming efficiency of TFG-ALK variants compared with NPM-ALK. In addition, in common with NPM-ALK, the TFG-ALK proteins formed stable complexes with the signaling proteins Grb2, Shc, and PLC-gamma. In conclusion, these findings indicate that the TFG may use a variety of intronic breakpoints in ALK rearrangements generating fusion proteins of different molecular weights, but with similar transforming potential than NPM-ALK.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11943732      PMCID: PMC1867210          DOI: 10.1016/S0002-9440(10)62574-6

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  41 in total

1.  Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells.

Authors:  M N Nikiforova; J R Stringer; R Blough; M Medvedovic; J A Fagin; Y E Nikiforov
Journal:  Science       Date:  2000-10-06       Impact factor: 47.728

Review 2.  Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.

Authors:  H G Drexler; S M Gignac; R von Wasielewski; M Werner; W G Dirks
Journal:  Leukemia       Date:  2000-09       Impact factor: 11.528

Review 3.  CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.

Authors:  H Stein; H D Foss; H Dürkop; T Marafioti; G Delsol; K Pulford; S Pileri; B Falini
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

4.  A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma.

Authors:  M Trinei; L Lanfrancone; E Campo; K Pulford; D Y Mason; P G Pelicci; B Falini
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

5.  ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35).

Authors:  G W Colleoni; J A Bridge; B Garicochea; J Liu; D A Filippa; M Ladanyi
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

6.  Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis.

Authors:  Z Ma; J Cools; P Marynen; X Cui; R Siebert; S Gesk; B Schlegelberger; B Peeters; C De Wolf-Peeters; I Wlodarska; S W Morris
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

7.  Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like).

Authors:  C Touriol; C Greenland; L Lamant; K Pulford; F Bernard; T Rousset; D Y Mason; G Delsol
Journal:  Blood       Date:  2000-05-15       Impact factor: 22.113

8.  Biochemical detection of novel anaplastic lymphoma kinase proteins in tissue sections of anaplastic large cell lymphoma.

Authors:  K Pulford; B Falini; J Cordell; A Rosenwald; G Ott; H K Müller-Hermelink; K A MacLennan; L Lamant; A Carbone; E Campo; D Y Mason
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

9.  Lymphomas expressing ALK fusion protein(s) other than NPM-ALK.

Authors:  B Falini; K Pulford; A Pucciarini; A Carbone; C De Wolf-Peeters; J Cordell; M Fizzotti; A Santucci; P G Pelicci; S Pileri; E Campo; G Ott; G Delsol; D Y Mason
Journal:  Blood       Date:  1999-11-15       Impact factor: 22.113

10.  Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway.

Authors:  R Y Bai; T Ouyang; C Miething; S W Morris; C Peschel; J Duyster
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

View more
  25 in total

1.  5'-(RACE) identification of rare ALK fusion partner in anaplastic large cell lymphoma.

Authors:  N Scott Reading; Stephen D Jenson; Jeffrey K Smith; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  J Mol Diagn       Date:  2003-05       Impact factor: 5.568

2.  The PB1 domain and the PC motif-containing region are structurally similar protein binding modules.

Authors:  Sosuke Yoshinaga; Motoyuki Kohjima; Kenji Ogura; Masashi Yokochi; Ryu Takeya; Takashi Ito; Hideki Sumimoto; Fuyuhiko Inagaki
Journal:  EMBO J       Date:  2003-10-01       Impact factor: 11.598

Review 3.  Novel approaches in anaplastic thyroid cancer therapy.

Authors:  Kun-Tai Hsu; Xiao-Min Yu; Anjon W Audhya; Juan C Jaume; Ricardo V Lloyd; Shigeki Miyamoto; Tomas A Prolla; Herbert Chen
Journal:  Oncologist       Date:  2014-09-26

4.  Identification of gene fusions from human lung cancer mass spectrometry data.

Authors:  Han Sun; Xiaobin Xing; Jing Li; Fengli Zhou; Yunqin Chen; Ying He; Wei Li; Guangwu Wei; Xiao Chang; Jia Jia; Yixue Li; Lu Xie
Journal:  BMC Genomics       Date:  2013-12-09       Impact factor: 3.969

5.  Identification of cancer fusion drivers using network fusion centrality.

Authors:  Chia-Chin Wu; Kalpana Kannan; Steven Lin; Laising Yen; Aleksandar Milosavljevic
Journal:  Bioinformatics       Date:  2013-03-16       Impact factor: 6.937

Review 6.  ALK-immunoreactive neoplasms.

Authors:  Parham Minoo; Huan-You Wang
Journal:  Int J Clin Exp Pathol       Date:  2012-05-23

Review 7.  Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.

Authors:  Andres Morales La Madrid; Andres Morales La Madrid; Nicholas Campbell; Sonali Smith; Susan L Cohn; Ravi Salgia
Journal:  Target Oncol       Date:  2012-09-12       Impact factor: 4.493

Review 8.  Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.

Authors:  Bengt Hallberg; Ruth H Palmer
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

9.  ced-4 and proto-oncogene tfg-1 antagonistically regulate cell size and apoptosis in C. elegans.

Authors:  Ling Chen; Tom McCloskey; Pradeep M Joshi; Joel H Rothman
Journal:  Curr Biol       Date:  2008-07-22       Impact factor: 10.834

Review 10.  Anaplastic lymphoma kinase: signalling in development and disease.

Authors:  Ruth H Palmer; Emma Vernersson; Caroline Grabbe; Bengt Hallberg
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.